LHLise Brehm Hoej

Lise Brehm Hoej

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lise Brehm Hoej has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Henning Grønbæk

    Department of Hepatology and Gastroenterology Aarhus University Hospital Aarhus Denmark

    2 shared publications
  • Cindy Soendersoe Knudsen

    Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark

    1 shared publication
  • Karen Marie Nykjær

    Department of Medicine V (Hepatology and Gastroenterology), Aarhus University Hospital, 8000 Aarhus, Denmark

    1 shared publication
  • Tina Parkner

    Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark

    1 shared publication

Latest Publications

  • Open Access

    A Comparison of ree Chromogranin A Assays in Patients with Neuroendocrine Tumours

    by Lise Brehm Hoej, Tina Parkner, Cindy Soendersoe Knudsen, Henning Grønbaek

    Background & Aims: Chromogranin A (CgA) is the most important general tumour marker used in the diagnosis and follow-up of patients with neuroendocrine tumours (NET). Chromogranin A assays may have different sensitivities, which is of importance for the clinical diagnosis and handling of NET patients. The aim of this study was to compare the clinical sensitivities of three different CgA assays in NET patients.Methods: We measured CgA level in 42 NET patients (male/female: 23/19, median age: 63 years, range 29- 85 years). Twenty-five patients had liver metastases, eight had local disease, and nine were disease free after surgery. We studied an in-house RIA: RH RIA assay (Rigshospitalet, Copenhagen, Denmark); NEOLISATM (Euro Diagnostica, Malmö, Sweden) and EURIA CgA RIA (Euro Diagnostica, Malmö, Sweden).Results: The RH RIA assay showed a clinical sensitivity of 97%, while the NEOLISA and EURIA assays both showed similar clinical sensitivities of 79%. Patients with liver metastases had significantly higher CgA levels compared to disease free patients by all three assays (P<0.001), but only the RH RIA assay was able to discriminate between patients with liver metastases and with regional disease (P<0.01).Conclusion: Chromogranin A measurements are significantly assay-dependent and caution should be applied in the interpretation of CgA measurement for assessment of NET status. The in-house RH RIA assay was better at predicting NET status than the NEOLISA and EURIA assays.List of abbreviations: CgA: chromogranin A; EURIA: Eurodiagnostica, radioimmunoassay; GFR: glomerular filtration rate; NEOLISA: Eurodiagnostica, enzyme-linked immunosorbent assay; NET: neuroendocrine tumour; PET-CT: positron emission tomography; PPI: proton pump inhibitor; RH RIA: Rigshospitalet, radioimmunoassay ; SPECT-CT: single photon emission computed tomography.


  • Open Access

    Incidence and Survival of Patients with Small Intestinal Neuroendocrine Tumours in a Danish NET Center

    by Lise Brehm Hoej, Karen Marie Nykjær, Henning Gronbaek

    Introduction. Small intestinal neuroendocrine tumours (NETs) have increased in incidence during the past decades. In recent years, new promising treatment modalities have been introduced. The aim of the present study was to characterize and compare patients with small intestinal NET seen in the periods 1994–2003 (group 1) and 2004–2011 (group 2) to demonstrate changes in incidence and survival in the two time periods.Patients and Methods. There were 52 NET patients in group 1 and 109 patients in group 2.Results. The incidence of small intestinal NET was 0.3/100.000/year in period 1 and 0.7/100.000/year in period 2. There was no difference in median chromogranin A levels (8709 versus 2381 pmol/L,P=0.107), presence of liver metastases (56% versus 44%), clinical symptoms (flushing/diarrhea), or Ki67 index (2% versus 2%), between the two time periods. The 5-year survival rate in the two time periods was similar, 64.7%, and 77.0%, respectively, (P=0.23).Conclusion. We observed an increase in the incidence of small intestinal NET during the period from January 1994 to December 2011, but we were not able to demonstrate an improved survival during the same time period.